Merck KGaA: CHMP OKs label update for MS drug Rebif

(CercleFinance.com) - Germany's Merck said that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion to update the label of its multiple sclerosis drug Rebif, saying women may continue treatment during pregnancy if clinically needed and while breastfeeding.


Merck also announced today that new data for several key therapeutic agents of its oncology pipeline will be presented at the congress of the European Society for Medical Oncology (ESMO), starting this week in Barcelona.

The drugmaker plans to present new subgroup analyses for first-line treatment of advanced renal cell carcinoma with Bavencio in combination with Pfizer's axitinib.

It will also unveil three-year overall survival data for patients treated first-line with Erbitux plus Folfox-4 in metastatic colorectal cancer.

Copyright (c) 2019 CercleFinance.com. All rights reserved.